View Post

Pfizer Receives European Approval for ZIRABEV™ (bevacizumab), a Biosimilar to Avastin®*

In In The News by Barbara Jacoby

From: argus-press.com Pfizer Inc. (NYSE: PFE) today announced the European Commission (EC) has approved ZIRABEV™ for the treatment of metastatic carcinoma of the colon or rectum, metastatic breast cancer, unresectable advanced, metastatic or recurrent non-small cell lung cancer (NSCLC), advanced and/or metastatic renal cell cancer and persistent, recurrent or metastatic carcinoma of the cervix. 1,2 “Pfizer is dedicated to increasing …

View Post

Biosimilars create opportunities for sustainable cancer care

In In The News by Barbara Jacoby

Biosimilars create opportunities for sustainable cancer care, says the European Society for Medical Oncology (ESMO) in a position paper published in ESMO Open.1 The document outlines approval standards for biosimilars, how to safely introduce them into the clinic, and the potential benefits for patients and healthcare systems. “Biosimilars are an excellent opportunity to have good, valid drug options that improve …